Immune escape by Epstein-Barr virus associated malignancies by Münz, C & Moormann, A
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Immune escape by Epstein-Barr virus associated malignancies
Münz, C; Moormann, A
Münz, C; Moormann, A (2008). Immune escape by Epstein-Barr virus associated malignancies. Seminars in Cancer
Biology, 18(6):381-387.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Seminars in Cancer Biology 2008, 18(6):381-387.
Münz, C; Moormann, A (2008). Immune escape by Epstein-Barr virus associated malignancies. Seminars in Cancer
Biology, 18(6):381-387.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Seminars in Cancer Biology 2008, 18(6):381-387.
Immune escape by Epstein-Barr virus associated malignancies
Abstract
Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers,
despite the potent growth transforming potential of this virus. The increased frequency of EBV
associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic
infection with this virus is in part due to immune control. Here we discuss the evidence that loss of
selective components of EBV specific immunity might contribute to EBV associated malignancies, like
nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent
patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target
these selective deficiencies.
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a b s t r a c t
Persistent Epstein–Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers,
despite thepotent growth transformingpotential of this virus. The increased frequencyof EBVassociatedB
cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this
virus is in part due to immune control. Here we discuss the evidence that loss of selective components of
EBV speciﬁc immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma,
Burkitt’s and Hodgkin’s lymphoma, in otherwise immune competent patients. Furthermore, we discuss
how current vaccine approaches against EBV might be able to target these selective deﬁciencies.
© 2008 Elsevier Ltd. All rights reserved.
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1. Immune escape mechanisms of latent EBV infection
Epstein–Barr virus (EBV) is a ubiquitous 1-Herpesvirus that
infects more than 90% of the human adult population. The virus
establishes persistent infection through its latency in B cells, from
which it continuously reactivates lytic replication to produce infec-
Abbreviations: AID, activation induced deaminase; BART, BamHI A rightward
transcript; EBER, EBV-encoded RNAs; EBNA, EBV nuclear antigen; EBV, Epstein–Barr
virus; HRS cells, Hodgkin–Reed-Sternberg cells; IM, infectious mononucleosis;
KSHV, Kaposi’s sarcoma herpesvirus; LCL, lymphoblastoid cell line; LMP, latent
membrane protein; NPC, nasopharyngeal carcinoma; MVA, modiﬁed vaccinia virus
Ankara; PEL, primary effusion lymphoma; PfEMP1, P. falciparum erythrocyte mem-
brane protein 1; PTLD, post-transplant lymphoproliferative disease; TLR, toll-like
receptor.
∗ Corresponding author at: Viral Immunobiology, Institute of Experimental
Immunology, University Hospital of Zurich, Winterthurerstrasse 190, CH-8057
Zurich, Switzerland. Tel.: +41 44 635 3716; fax: +41 44 635 6883.
E-mail address: christian.muenz@usz.ch (C. Münz).
tious viral particles for transmission. While it expresses more than
80 lytic antigens, latently infected cells express up to 8 proteins
and several non-translated RNAs [1]. The non-translated RNAs are
the BamHI A rightward transcripts (BARTs), which are thought to
give rise to EBVencodedmicroRNAs [2], and the EBV-encodedRNAs
(EBERs), which have been suggested to protect EBV infected cells
from apoptosis [3]. Of the six latent EBV proteins, six are nuclear
antigens (EBNA1, 2, 3A, 3B, 3C, LP) and two are membrane proteins
(LMP1 and 2). This limited antigen expression is probably one of
the essential immune escape mechanisms of latent EBV infection,
while EBV expressesmore than 80 antigens during lytic replication.
In addition to reduced viral protein expression, the virus performs
some latency functions with non-translated RNAs which cannot
be detected by T cells looking for small peptides presented on
MHC class I and IImolecules. EBV reduces antigenic protein expres-
sion further, dependent on the differentiation stage of the latently
infected B cell [4]. While all eight latent EBV antigens can be found
in naïve B cells in tonsils, the primary site of EBV infection after
1044-579X/$ – see front matter © 2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.semcancer.2008.10.002
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Fig. 1. EBV associated lymphomas are thought to primarily develop from two
latency states. All eight latent EBV antigens can be found expressed in naïve B cells
of healthy virus carriers. Only substantial immune escape by immune suppression
from dominant and subdominant CD4+ (EBNA1 and LMP speciﬁc, respectively) and
CD8+ (EBNA3 and EBNA1, LMP1, respectively) T cell responses can lead to PTLD and
HIV-associated diffuse large cell lymphoma. In contrast, the restricted latency pat-
tern ofHodgkin’s lymphomaonly needs to escapedominant and subdominant CD4+,
and CD8+ T cell responses of intermediate and low dominance. Finally, Burkitt’s
lymphoma, which probably also develops from germinal center B cells, shuts down
latent EBV infection even further and prevents, due to its constitutively active c-myc
activity, LMP expression. Burkitt’s lymphoma, therefore, has only to compromise
dominant CD4+ and subdominant CD8+ T cell responses against EBNA1 to escape
from immune control (red circles: CD4+ T cells, blue circles CD8+ T cells, grouped
into dominant, intermediate and subdominant responses).
transmission in saliva, germinal center B cells express only EBNA1,
LMP1 and LMP2 (Fig. 1) [5]. Furthermore, infected peripheral blood
memory B cells express no EBV antigens or EBNA1 during home-
ostatic proliferation [6]. Therefore, memory B cells, harboring the
EBV genome without any EBV protein expression, are probably the
site of long-term EBV persistence [7], and invisible to the immune
system.
In addition to the reduced number of viral protein expression
during latent infection, the copy number of the expressed EBV anti-
gens and of the antigenic peptides processing forMHCpresentation
from these is also kept very low. EBNA1 prevents efﬁcient transla-
tion by a glycine–alanine encoding repeats (GA domain) [8]. The
same GA repeat domain inhibits proteasomal processing for efﬁ-
cientMHC class I presentation of EBNA1 [9,10]. In addition, EBNA3C
limits its protein copy expression to a low level, fromwhich antigen
processing and MHC class I presentation can display only less than
one peptide per cell [11]. All this evidence suggests that EBV down-
regulates detection by limiting the expressed viral protein number
aswell as the copynumberper viral protein asmain immuneescape
mechanisms during latent infection.
Despite the sophistication of the antigen down-regulation dur-
ing latent EBV infection, every infected individual develops T and
B cell responses to the latent EBV antigens, and these are thought
to keep persistent EBV infection in check and avoid EBV associ-
ated malignancies in most persistently infected individuals. In the
following we will however discuss environmental circumstances,
like coinfections, and changes in the tumor microenvironment,
that favor the development of EBV associated malignancies. A
good understanding of these changes is obviously instrumental to
develop speciﬁc treatments of these EBV associated tumors and to
determine possible cancer prevention strategies.
2. Manipulation of EBV speciﬁc immune control by
coinfections
2.1. HIV associated lymphomas
One environmental trigger for the emergence of EBV associated
malignancies is the coinfection with the human immunodeﬁ-
ciency virus (HIV). Since HIV infection causes progressive immune
suppression, leading to the acquired immunodeﬁciency syn-
drome (AIDS), different EBV associated lymphomas develop at
different stages of HIV infection [12]. Primarily HIV coinfection
promotes the development of EBV associated non-Hodgkin’s lym-
phomas of three types. Firstly, immunoblastic or diffuse large
cell lymphomas develop after considerable immunosuppression
by HIV, and also give rise to the central nervous system (CNS)
lymphomas in AIDS patients [13]. These lymphomas carry all
latent EBV antigens and are therefore probably comparable to
post-transplant lymphoproliferative disease (PTLD), in that quite
extensive immunosuppression allows for the escape of EBV from
nearly all EBV latent antigen speciﬁc immune control mechanisms,
and proliferation of B cells via the most aggressive EBV latency
program (Fig. 1). Secondly, EBV joins forces with another human
-herpesvirus, Kaposi’s sarcoma herpesvirus (KSHV) in the devel-
opment of primary effusion lymphoma (PEL), which is frequently
coinfected by both herpesviruses [14]. While PEL is a rare tumor in
immunocompetent individuals it arises with increased incidence
rates in HIV infected patients. Interestingly, PEL expresses EBNA1
as the only EBV protein, but gains resistance against apoptosismost
likely via the expression of this protein as well as non-translated
EBV RNAs [15,3,16]. In addition, KSHV contributes to PEL prolif-
eration probably through upregulation of the cellular oncogene
c-myc [17]. Thirdly, EBV associated small noncleaved lymphomas
also develop in HIV infected individuals, and within this category
30–40% of AIDS associated Burkitt’s lymphomas are EBV positive
[18]. While c-myc is deregulated in PEL by KSHV infection, it is
translocated into one of the immunoglobulin loci in Burkitt’s lym-
phoma and stimulates proliferation of Burkitt’s lymphoma cells
in this way [19]. In addition, most EBV associated Burkitt’s lym-
phomas express the same EBV latency program as PELs (Fig. 1),
contributing to apoptosis resistance of these tumors [15]. The later
two categories of AIDS associated EBV positive lymphomas, PEL
and Burkitt’s lymphoma, develop earlier after HIV infection with
Burkitt’s lymphoma being often one of the earliest manifestations
of AIDS [18].
Accordingly, two independent studies have found that selec-
tive loss of EBV speciﬁc CD4+ T cell responses correlates with the
development of EBV associated non-Hodgkin’s lymphomas in HIV
infected individuals [20,21]. Piriou and colleagues even described
that CD4+ and CD8+ T cell responses against EBNA1, the only EBV
protein expressed in Burkitt’s lymphoma and PEL, were severely
compromised inHIV infected individuals that developedAIDSasso-
ciated EBV positive lymphomas, while T cell responses against the
immediate early lytic EBV antigen BZLF1 were maintained in these
patients [20]. This indicated that the selective loss of one partic-
ular immune response against EBV predisposes AIDS patients for
EBV associated lymphomas. In another study, it was noted that HIV
patients who developed EBV associated primary CNS lymphomas
had lost EBV speciﬁc IFN- responses by CD4+ T cells despite main-
taining healthy absolute CD4+ T cell counts [21], again arguing that
a selective loss of EBV speciﬁc CD4+ T cell immune control predis-
poses for the development of EBV associated lymphomas in AIDS
patients. EBV speciﬁc CD4+ T cells might be especially important to
prevent AIDS associated PEL and Burkitt’s lymphoma since EBNA1,
the only EBV protein expressed in these tumors, inhibits its pro-
cessing onto MHC class I [22], but is recognized by CD4+ T cells
Author's personal copy
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after intracellular processing via macroautophagy [23,24]. There-
fore, EBNA1 speciﬁc CD4+ T cells are capable to recognize Burkitt’s
lymphomacells [25,26], even so this tumordown-regulates antigen
processing towards MHC class I presentation via c-myc overex-
pression, and therefore escapes CD8+ T cell immune surveillance
[27,28,26,29,30]. These studies suggest that already early during
HIV infection, when absolute CD4+ T cell counts are still main-
tained at normal levels, selective EBV speciﬁc CD4+ T cell responses,
primarily directed against EBNA1, get depleted, and susceptibil-
ity to EBV associated lymphomas, particularly PEL and Burkitt’s
lymphoma increases. One could even speculate that antigen per-
sistence due to EBV latency activates these EBV speciﬁc CD4+ T
cell preferentially, and makes them vulnerable to HIV infection.
Irrespective of the mechanism, this preferential depletion of EBV
speciﬁc immune control might lead to EBV associated lymphomas
in AIDS patients.
2.2. Endemic Burkitt’s lymphoma
In addition to HIV infection, EBV associated malignancies are
also associated with malaria. Indeed, the tumor, in which EBV was
originally visualized is the most common childhood tumor in Sub-
Saharan Africa and occurs mainly in holoendemic malaria regions
of Africa and Papua New Guinea, where individuals are repeat-
edly infected with Plasmodium falciparum. This B cell lymphoma,
endemic in Africa, is nearly 100% EBV associated [31,32]. Similar, to
HIV associatedBurkitt’s lymphoma, endemicBurkitt’s lymphoma is
characterizedbyac-myc translocation intooneof the immunoglob-
ulin loci and expresses EBNA1 as the only EBVprotein togetherwith
non-translated viral RNAs [33].
Despite its discovery 50 years ago the etiology of Burkitt’s lym-
phoma is still unclear. Two alternate though not mutually exclusive
explanations for a role of malaria in Burkitt’s lymphomagenesis
are discussed. One is that P. falciparum stimulates the B cell com-
partment, resulting eventually in a c-myc translocation in an EBV
infected B cell as a side effect of somatic hypermutation of acti-
vated B cells in the germinal center reaction (Fig. 1). The alternate
explanation is that malaria infection compromises EBV speciﬁc
immune control, leading to immune escape of an EBV infected B
cell including those in which a c-myc translocation has occurred.
Evidence for stimulation of the EBV infected B cell compartment
has indeed been found in children from endemic malaria regions.
EBV reactivates from this reservoir probably after B cell receptor
stimulation and lytic EBV replication is primarily found in plasma
cells [34]. Accordingly, circulating EBV was detected in malaria
infected children [35–37], and elevated antibody titers against lytic
EBVantigens are associatedwith endemicBurkitt’s lymphoma [38].
Two main B cell activation pathways have been suggested that
potentially give rise to c-myc translocation in EBV infected B cells.
Firstly, P. falciparum antigens, like the merozoite surface proteins
[39], trigger B cell responses, and it has been shown that acti-
vation induced cytidine deaminase (AID) expression in germinal
centers, to which activated B cells home, is required for c-myc
translocation and lymphoma development [40–42]. In addition to
malaria antigen induced B cell activation for AID upregulation,
EBV LMP1 mediated B cell activation has also been described to
upregulate AID [43]. Secondly, the P. falciparum erythrocyte mem-
brane protein 1 (PfEMP1) is a polyclonal B cell activator and has
been shown to trigger lytic EBV replication in infected B cells
[44]. Other pathogen patterns for B cell activation like toll-like
receptor (TLR) ligands have been identiﬁed in malaria [45], but
how this may increase the risk of EBV associated lymphomas
has yet to be explored. Therefore, malaria might have the means
to directly activate EBV infected B cells to develop into Burkitt’s
lymphoma.
In addition, however, these cells might need to escape EBV
speciﬁc immune control. Indeed, T cell mediated immune con-
trol of EBV infected B cells was found to be compromised in
malaria infected individuals [46]. Especially in children, in which
both malaria and EBV speciﬁc immune control need to develop
simultaneously, immune suppressive effects of P. falciparum might
impair the efﬁcient establishment of cell-mediated EBV speciﬁc
immunecontrol. Accordingly, higher EBV loads, indicativeof dimin-
ished EBV speciﬁc immune control, have been detected in children
of holoendemic malaria regions [36]. This P. falciparum mediated
immune suppression could originate from its ability to inhibit
early IFN- production via PfEMP1 mediated inhibition [47], and
the ability of large numbers of Plasmodium infected erythrocytes
to inhibition of immune responses by dendritic cells (DCs) [48].
Whatever the mechanism, impaired EBV speciﬁc immune control
might contribute to Burkitt’s lymphoma development in children
of holoendemicmalaria regions. In characterizing speciﬁc deﬁcien-
cies, a lower percentage of 5–9 year old children in holoendemic
malaria regions recognized dominant CD8+ T cell epitopes from
EBV than children from a neighboring region with sporadic malaria
transmission [49]. However, in the responding children the magni-
tude of EBV speciﬁc CD8+ T cellswas not signiﬁcantly different from
age matched controls. In contrast to this rather mild deregulation
of EBV speciﬁc CD8+ T cell control, T cell responses against EBNA1,
the only EBV protein expressed in the majority of Burkitt’s lym-
phomas, were signiﬁcantly decreased in nearly all children with
Burkitt’s lymphoma, while CD4+ T cell responses against malaria
antigens and CD8+ T cell responses against other EBV antigens
were intact [93]. These results suggest that selective deﬁciencies in
EBV speciﬁc immune control assist in the development of Burkitt’s
lymphoma,while P. falciparummediated activation of the B cell sys-
tem generate a higher frequency of Burkitt’s lymphoma precursor
cells.
In addition, to these EBV associated malignancies arising in the
presence of immune compromising coinfection, some EBV associ-
ated tumors seem to condition their microenvironment to induce
local or even selective systemic immunosuppression for their
growth in otherwise immunocompetent individuals. The two best
characterized examples are EBV associated Hodgkin’s lymphoma
and nasopharyngeal carcinoma (NPC), which we will discuss next.
3. Tumor microenvironments conditioned by EBV positive
tumors
3.1. Nasopharyngeal carcinoma
Nasopharyngeal carcinoma is a frequent epithelial cell cancer
with ahigh incidence rate in Southeast China, especially theGuang-
dong province and neighboring Hong Kong [50]. Since epithelial
infection by EBV can be demonstrated in vitro [51], but has not been
convincingly documented in vivo, the etiology of this tumor is still
quite mysterious. However, it has been clearly documented that
EBV is present in 100% of NPCs, and establishes a latency pattern
with EBNA1 and LMP1 or LMP2 protein expression [52]. Early after
the discovery of EBV associationwithNPC a deregulation of the EBV
speciﬁc immune response with elevated IgA titers against the virus
was noted [53]. This indicated that the immune response at the
site of tumor development was changed, and that the tumor might
condition its microenvironment to facilitate growth. Indeed recent
studies support the notion that local immune suppression rather
that systemic deﬁciency in EBV speciﬁc immune controlmight con-
tribute to NPC development [54,55]. In these studies, EBV speciﬁc
CD4+ and CD8+ T cell responses could be reactivated from periph-
eral blood of NPC patients [54,55]. Even though LMP1 and LMP2
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speciﬁc CD8+ T cells were enriched in tumor inﬁltrating lympho-
cytes, their cytotoxicity and cytokine secretion was impaired [55].
This impairment could be due to the presence of CD4+CD25+FoxP3+
natural regulatory T cells in the tumor tissue, which could sup-
press EBVspeciﬁc immune responses againstNPCevenafter correct
homing of effector T cells [56,55].
In addition to active T cell suppression at the tumor site, the
efﬁciencywithwhichNPC canpresent antigens to T cellsmight also
be compromised. While earlier studies based on a limited number
of NPC cell lines suggested that antigen processing for MHC class
I presentation was intact in NPC cells [57,58], a more recent study
on primary tumor tissues suggested that the MHC class I antigen
processing machinery is down-regulated in the majority of tumors
[59]. Even though no functional deﬁciency of MHC class I antigen
presentation could be tested in this later study, it makes it possible
to speculate that in addition to active immune suppression at NPC
tumor sites the recognition of tumor cells by CD8+ T cells is also
impaired. Together thesedata suggest thatNPC impairs EBVspeciﬁc
immune control locally, while allowing efﬁcient systemic immune
responses against this virus.
3.2. Hodgkin’s lymphoma
Hodgkin’s lymphoma is the most common EBV associated lym-
phoma in the US and Europe. Around 40% of Hodgkin’s lymphomas
are EBV associated [14]. Interestingly only a small subset of cells,
the so-called Hodgkin–Reed-Sternberg (HRS) cells, are the EBV
transformed tumor cells, primarily of B cell origin, in the tumor
tissue [60]. HRS cells harbor the restricted EBV antigen expres-
sion pattern found in germinal center B cells of healthy EBV
carriers (Fig. 1) [61]. The majority of cells in the tumor tissue
are inﬁltrating lymphocytes. This indicates that Hodgkin’s lym-
phoma has already managed to generate an immunosuppressive
environment that allows the tumor cells to grow despite exten-
sive homing of immune cells to the tumor site. A number of
immune escape mechanisms have been proposed and those can
be subdivided into immunosuppressive functions of the HRS cells
themselves and of the inﬁltrating lymphocytes. HRS cells have
been shown to produce immunosuppressive cytokines like IL-
10, IL-13 and TGF- [62–64]. IL-13 has been demonstrated to
enhance HRS cell proliferation in an autocrine fashion in addition
to its immune suppressive functions, which probably are primarily
mediated through the induction of IL-10 producing Th2 polarized
cells [63,65]. In addition to immunosuppressive cytokine produc-
tion by HRS cells, galectin-1 secretion could also contribute to
immune escape in Hodgkin’s lymphoma [66]. Elevated galectin-
1 levels have been reported in tumor biopsies and recombinant
galectin-1 has been shown to inhibit EBV speciﬁc T cell pro-
liferation and cytokine secretion. Therefore, HRS cells employ
several mechanisms, which are able to immune suppress their
microenvironment.
As a result of this, regulatory T (Treg) cell populations seem
to be enriched in Hodgkin’s lymphoma tissues. Several regulatory
CD4+ T cell populations have been described in Hodgkin’s lym-
phoma. Among the CD4+ Treg cells are IL-10 producing Tr1 cells
and CD4+CD25+ natural Treg cells [67]. These have been shown to
suppress peripheral blood cell proliferation and cytokine secretion
in an IL-10 and cell contact dependent fashion. In addition, LAG-3
positive CD4+ T cells have been recently described to be selectively
enriched in EBV positive Hodgkin’s lymphoma biopsies [68]. They
seem to be induced by soluble factors secreted by HRS cells and
suppress LMP speciﬁc T cell responses. Therefore, regulatory T cell
populations may suppress EBV speciﬁc immune control locally,
and this involves cell-contact as well as the immunosuppressive
cytokines IL-10 and TGF- [64].
In addition, to this local immune suppression, however, selec-
tive systemic impairment of EBV speciﬁc T cell responsesmight also
contribute toHodgkin’s lymphomadevelopment. Along these lines,
Hodgkin’s lymphoma patients have diminished EBNA1 speciﬁc
CD4+ T cell responses, while they maintain CD8+ T cell responses
against other latent and lytic EBV antigens [94]. These ﬁndings sug-
gest that immunotherapeutic approaches should be developed to
correct the selective systemic and tumor microenvironment spe-
ciﬁc deﬁciencies in EBV speciﬁc immune control. Since the tumor
cells do not seem to have defects in antigen processing for MHC
class I presentation [69,70], interventions to correct the selective
systemic loss of EBV speciﬁc T cell responses and to overcome the
local immune suppression in the tumor tissue should be explored
as treatments of this EBV associated malignancy and ideally such
modalities could be used for prevention in high risk populations.
4. Vaccine approaches against EBV associated malignancies
Recent evidence suggests that suboptimal initial immune
control of EBV, as evidenced by symptomatic seroconversion, pre-
disposes for the development of EBV associated disease. Along
these lines, the risk of developing Hodgkin’s lymphoma is fourfold
higher with a median incubation time of 4 years after resolution of
infectious mononucleosis (IM), which is symptomatic primary EBV
infection with high viral titers and therefore massively expanded,
primarily EBVspeciﬁcT cells [71]. Therefore, preventivevaccination
to avoid uncontrolled virus replication and successive “scaring” of
the immune system [72], could decrease the incidence of EBV asso-
ciated malignancies. For the prevention of IM, vaccines to induce
neutralizing antibodies and T cell responses are under develop-
ment. For the stimulation of EBV speciﬁc humoral immune control,
recombinant gp350, the major EBV surface glycoprotein, has been
tested. Itwas able to elicit neutralizing antibodies in aphase I/II trial
[73], but the vaccine’s efﬁcacy in preventing IM remains unclear.
Alternatively, a single CD8+ T cell epitope vaccine has been tested to
elicit protective immunity against IM [74]. While it was successful
in eliciting peptide speciﬁc T cell responses in a phase I clinical trial,
the number of vaccinated individuals was too low to allow conclu-
sions about its efﬁcacy. In addition to these preventive vaccines,
therapeutic immunizations against EBV associated malignancies
are also being pursued.
The most successful of these is passive immunization by adop-
tive transfer of EBV speciﬁc T cells. This approach was developed
from the observation that donor leucocyte infusions could be used
to treat PTLD [75]. It was further reﬁned by expanding EBV spe-
ciﬁc T cells from seropositive donors in co-cultures with irradiated
autologous EBV transformed B cells (LCLs) and injecting these
enriched cultures into PTLD patients [76]. This therapy is to date
the most commonly practiced passive immunotherapy involving T
cells. Unfortunately, expanding this success story toNPC, Hodgkin’s
and Burkitt’s lymphoma has proven difﬁcult, in part due to the
fact that LCL stimulation will primarily expand immunodominant
T cell responses, speciﬁc for the latent EBNA3 antigens, which are
not expressed in these tumors. In focusing in vitro T cell expan-
sions to the EBNA1, LMP1 and LMP2 antigens, which are present
in these malignancies, recombinant viruses encoding for these EBV
products have been utilized to expand speciﬁc CD8+ T cells, which
could protect against LMP positive tumor growth in mice in vivo
[77–79]. However, these T cell lines, targeting a select subset of
EBV antigens, are just now starting to be tested in patients. As an
alternative to passive immunization by adoptive T cell transfer EBV
antigen loaded DCs have been evaluated for inducing protective
CD8+ T cell responses against NPC. Although LMP2 speciﬁc CD8+ T
cells could be expanded after peptide pulsed DC injection in NPC
patients, these responses were too weak or transient to achieve
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clinical effects [80]. Thus, vaccine approaches that primarily tar-
get CD8+ T cells have not yielded sufﬁcient therapeutical success
against EBV associated lymphomas.
Learning from these trials and as a result of a better under-
standing of the crucial role for CD4+ T cells in assisting CD8+ T cell
immunity [81], more recent vaccine formulations aim to incorpo-
rate both CD4+ and CD8+ T cell antigens. In addition to CD4+ T cell
help forCD8+ Tcell responses, CD4+ Tcells canalso targetEBV trans-
formed B cells directly [25,82–84], adding to their value as vaccine
targets. As above with CD8+ T cell epitope pulsing, many of these
immunization strategies target DCs, which have been shown to be
more efﬁcient than LCLs in expanding EBV speciﬁc T cells [85] and
are capable of priming protective CD4+ and CD8+ T cell responses
against EBV transformed B cells in vitro [86]. CD4+ and CD8+ T
cells, expanded with DCs, which had been infected with a recom-
binant adenovirus encoding LMP2, were able to kill NPC cells [87].
Furthermore, recombinant modiﬁed vaccinia virus Ankara (MVA)
has been used to express a fusion protein between the immuno-
genic C-terminal domain of EBNA1, a reliable CD4+ T cell target
[23,88], and LMP2, which is frequently recognized by CD8+ T cells
[89]. DCs infected with this recombinant MVA were able to expand
EBNA1 speciﬁc CD4+ and LMP2 speciﬁc CD8+ T cell from seropos-
itive donors. Finally, EBNA1 can also be directly targeted to DCs
via fusion to antibodies that are speciﬁc for endocytic receptors on
DCs [95]. Hybrid antibodies reactive to the DC receptor DEC-205
and carrying EBNA1 were able to elicit EBV speciﬁc CD4+ and CD8+
T cell responses in vitro and in vivo. These approaches openpromis-
ing avenues to enhance or prime selective protective EBV speciﬁc
immune responses, whose absencemight predispose for the devel-
opment of EBV associated malignancies or which have been
suppressed by the tumor cells itself or their microenvironment.
5. Conclusions
There is now mounting evidence that in addition to growth
transforming contributions of both EBV and mutations, EBV asso-
ciated malignancies in otherwise immune competent individuals
escape immune control by either immune compromising coinfec-
tionor conditioningof theirmicroenvironment. Since these tumors,
like NPC, Hodgkin’s and Burkitt’s lymphoma express only a limited
group of EBV antigens, only a select group of the protective EBV
speciﬁc T cell responses needs to be compromised to allow their
emergence. The challenge of developing immunotherapies against
these EBVassociatedmalignancies lies now in formulating vaccines
comprised of relevant CD4+ and CD8+ T cell EBV antigens expressed
in these tumors with a potent adjuvant that will elicit protective
EBV speciﬁc Th1 immunity [90,91] with a strong central memory
component [92]. The consensus at the moment seems to be that
EBNA1 as a promising CD4+ T cell antigen, should be combined
with LMP1 and LMP2 for CD8+ T cell stimulation in such a vac-
cine for both prevention of symptomatic EBV infection as well as
immunotherapy against EBV associated malignancies.
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